© 1982 British Society for Rheumatology
research-article |
A DOUBLE-BLIND TRIAL COMPARING INDOMETHACIN SUSTAINED RELEASE CAPSULES (INDOCID-R) WITH INDOMETHACIN CAPSULES IN PATIENTS WITH RHEUMATOID ARTHRITIS
Merck Sharp&Dohme Research Laboratories Rahway, New Jersey, U.S.A. 07065
Correspondence to:
Requests for reprints to Dr. A.R. Rhymer
A doubleblind, controlled and completely randomized trial was conducted in four European rheumatology clinics. Eightysix patients with a diagnosis of rheumatoid arthritis and prior treatment of at least six months' duration with indomethacin 150 mg/day were studied. Comparisons of the clinical efficacy, tolerability and safety of a new, oral, sustainedrelease formulation of indomethacin were made with a conventional formulation of indomethacin. In all clinical indices of response, the indomethacin sustainedrelease 75 mg capsule b.i.d. was found to provide relief of symptoms similar to the conventional 50 mg capsule t.i.d. The incidence of overall adverse clinical and laboratory effects was comparable for the two treatments.